期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞周期素依赖性激酶抑制因子与肺癌

Cyclin dependent kinase inhibitor and lung cancer
下载PDF
导出
摘要 细胞周期素依赖性激酶抑制因子(CDKI)家族成员中,p16甲基化是肺癌早期诊断的标志之一,P21、P27或P57的高表达与肺癌的治疗预后相关。P16、P21和P27为有效的治疗靶点。目前小分子激动剂及基因治疗方法尚待进一步研究认证。本文综述CDKI(INK4家族和Cip/Kip家族)在肺癌的发生、诊断、治疗和预后等方面的研究进展,以及其作为肺癌治疗靶标的应用价值。 In the group of cyclin dependent kinase inhibitors （CDKI） the p16 methylation is one of the biomarkers for early diagnosis of lung cancer,and the over expressions of P21,P27 and P57 are related with its treatment and prognosis. Therefore,P16,P21 and P27 could be used as therapeutic targets of lung cancer. Currently,the researches on small molecule antagonists and gene therapy are in process. This review describes the latest advances on diagnosis,treatment and prognosis of lung cancer through CDKIs,INK4 （inhibitor of CDK4） group and Cip/Kip （CDK-interacting protein/kinase inhibition protein） group,and their applications as therapeutic targets.
作者 郭月芳 孙晓琴
机构地区 上海医药工业研究院药理研究室 上海中医药大学实验动物中心
出处 《世界临床药物》 CAS 2010年第8期495-499,共5页 World Clinical Drug
基金 国家"重大新药创制"科技重大专项资助(项目编号2009ZX09301-007)
关键词 细胞周期素依赖性激酶抑制因子 肺癌 基因 诊断 治疗 cyclin dependent kinase inhibitor lung cancer gene diagnosis therapy
分类号 R979.1 [医药卫生—药品] R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献42

  • 1杨振华,蔡映云,孙丽华,乔岩.p16^(INK4a)和RASSF1a启动子甲基化在非小细胞肺癌中的研究[J].实用肿瘤杂志,2007,22(2):153-156. 被引量：4
  • 2Jones P A, Baylin S B. The fundamental role of epigenetie events in cancer [ J].Nat Ray Genet , 2002 , 3 ( 6 ) : 415 - 428.
  • 3Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermcthylation of RASSF1 A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers[ J]. Lung Cancer, 2007,58 (1) :131- 138.
  • 4Belinsky S A, Palmisano W A, Gilliland F D, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers [ J ]. Cancer Res, 2002, 62 (8) :2370-2377.
  • 5Pulling L C , Divine K K, Klinge D M, et al. Promoter hypennethylation of the O6-methyluanine-DNA methyltransferase gene: more common in lung adenocarcinomas from neversmokers than smokers and associated with tumor progression [ J ]. Cancer Res ,2003 ,63 (16) :4842-4848.
  • 6Russo A L, Thiagalingam A, Pan H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoker-induced neoplastic progression of lung cancer [ J ] . Clin Cancer Res, 2005 , 11 (7) :2466-2470.
  • 7Burbee D G, Forgacs E, Zochbauer- Muller S, et al. Epigenetie inactivation of RASSF1 A in lung and breast cancers and malignant phenotype suppression [ J ]. J Natl Cancer lnst, 2001 ,93 (9) : 691-699.
  • 8Dammann R, Schagdarsurengin U, Seidel C, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update [ J ] . Histopathology, 2005,20 ( 2 ) : 645 -663.
  • 9Liu Y , Lan Q, Siegfried J M, et al. Aberrant promoter methy- lation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients [ J ]. Neoplasia, 2006,8 (1) :46-51.
  • 10Liu Y, Gao W, Siegfried J M, et al. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers [ J ]. BMC Cancer, 2007,7:74.

共引文献33

世界临床药物
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部